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Abstract
Eosinophilic esophagitis (EoE) is a chronic immune-mediated condition where infiltration of
eosinophils into the esophageal mucosa leads to symptoms of esophageal dysfunction. It has
rapidly emerged as an important cause of upper GI morbidity in patients of all ages and is
encountered in a substantial proportion of patients undergoing diagnostic upper endoscopy. This
review discusses the clinical, endoscopic, and histologic features of EoE and presents the most
recent guidelines for diagnosis of EoE. It describes selected diagnostic dilemmas including
distinguishing EoE from gastroesophageal reflux disease and addressing the newly recognized
clinical entity of proton pump inhibitor responsive esophageal eosinophilia. It also highlights
evidence to support both pharmacologic and non-pharmacologic treatments, including topical
corticosteroids, dietary elimination therapy, and endoscopic dilation.
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Introduction
Eosinophilic esophagitis (EoE) is currently defined as a chronic immune-mediated condition
where infiltration of eosinophils into the esophageal mucosa leads to symptoms of
esophageal dysfunction.1 While the first case was described in the late 1970s,2 the disease as
it is now recognized was reported in children and adults in the early 1990s.3-5 EoE was
initially felt to be rare, but data from multiple centers now show that the incidence and
prevalence are increasing rapidly and have outpaced the increased recognition of the
disease.6-12 In fact, over the past ten years EoE has become an important and frequent cause
of upper gastrointestinal symptoms in both children and adults.13,14 More than 6% of
patients undergoing upper endoscopy for any reason, and more than 15% having the
procedure for an indication of dysphagia will be diagnosed with EoE.15-17 The prevalence of
EoE has been estimated to range between 43-52/100,000 in the general population,10,18,19 a
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level that is beginning to approach the population prevalence of inflammatory bowel
disease.20
The increasing recognition and evolving epidemiology of EoE has led to an explosion of
research interest. While many questions related to EoE are unanswered, there has been
substantial progress towards understanding the pathogenesis and genetic basis of the
disease,21-23 the clinical presentation, and effective treatment strategies. This review will
discuss clinical, endoscopic, and histologic features of EoE, present the most recent
guidelines for diagnosis of EoE and selected diagnostic dilemmas, and highlight evidence to
support both pharmacologic and non-pharmacologic treatment.
Patient history
EoE has been described throughout the world including North America, Europe, South
America, Australia, and Asia, but the prevalence appears to be highest in the U.S. and
Western Europe as compared with Japan and China.9,10,19,24-26 It also occurs in patients of
all ages,1,27,28 ut it is more frequent in children and adults under the age of 40.27-29 For
reasons that are not understood, EoE is seen three to four times more frequently in males
than in females, and is also more common in whites.1,8,9,16,17,28,30 However, as centers
accrue more experience and report data from larger populations of subjects from more
diverse areas, racial minorities have been found to have EoE.31-34
The clinical presentation of EoE varies by patient age.1,6,8,35,36 In infants and toddlers,
symptoms are non-specific, and can include failure-to-thrive, fussiness, poor growth,
feeding intolerance or food aversion, abdominal pain, nausea, vomiting, and
regurgitation.29,35,37 In contrast, dysphagia is the most characteristic symptom in
adolescents and adults, and in some studies this symptom is nearly universal.8,15,17,28,29 For
patients who present to an emergency department with a food impaction, EoE is the cause at
least 50% of the time.38-40 It is important to note that patients can minimize symptoms of
dysphagia by avoiding solid foods, lubricating foods, drinking copious liquids during meals,
and chewing carefully, so asking about these dietary modifications on history is necessary.
Heartburn can affect patients with EoE of any age, and in 1-8% of those with proton-pump
inhibitor (PPI) refractory reflux symptoms, EoE is the cause.15,17,29,41-44 Because of the
many potential symptoms and because no single symptom is specific for EoE, there is often
a delay in making the diagnosis.45
EoE is also strongly associated with atopic diseases such as asthma, allergic rhinitis and
sinusitis, atopic dermatitis, and food allergies. This relationship was first reported in children
where up to 80% can have atopy, and helped to support the allergic etiology of
EoE.29,37,46,47 While fewer adults with EoE have atopy, it is still a prominent feature in this
population.8,48,49 Interestingly, there have been several reports of seasonal variation in the
diagnosis of EoE as well as variation based on climate zone.8,9,50,51
Endoscopic features
Upper endoscopy is required to evaluate the clinical symptoms of EoE, assess for other
possible causes, and perform esophageal biopsies. Multiple characteristic endoscopic
findings of EoE have been reported,1,52-54 but in up to 10% of cases the esophageal mucosa
can appear normal and biopsies are required or the diagnosis will be missed.55 These
findings have a fair to good inter- and intra-observer reliability,56,57 and efforts are
underway to standardize reporting and scoring of endoscopic findings in EoE.58
Typical endoscopic findings of EoE are presented in Figure 1, and include:
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• Esophageal rings. These can be fixed (previously referred to as esophageal
trachealization or corrugation) or transient (sometimes termed felinization).
• Narrow caliber esophagus. This can be difficult to appreciate on visual inspection
alone, but there can be resistance to the scope passage without seeing a clear
stricture.
• Focal esophageal strictures.
• Linear furrows. These are grooves in the esophageal mucosa that run parallel to the
axis of the esophagus.
• White plaques or exudates. These are punctate white spots on the esophageal
mucosa that can be confused for esophageal candidiasis.
• Decreased vascularity. Here, the normal mucosal vascular pattern is lost and the
esophagus appears pale, congested, or edematous.
• Crêpe-paper mucosa. This is a manifestation of mucosal fragility in EoE where the
mucosa tears with passage of the endoscope, but a focal stricture or resistance is not
appreciated.
These features can occur in isolation, but more commonly occur together. There are some
data to suggest that younger children tend to have more inflammatory features such as linear
furrows, white plaques, and decreased vasculature, while adults (particularly those with a
long symptom duration) tend to have more fibrotic features such as rings and
strictures.8,59,60 It is important to note that the endoscopic findings of EoE are not
pathognomonic, and a recent meta-analysis found that the sensitivity, specificity, and
predictive values of endoscopic findings in EoE were not high enough to be the basis for
diagnostic decisions. This emphasizes the importance obtaining esophageal biopsies when
EoE is suspected clinically. This is reiterated in recent guidelines which recognize that the
eosinophilic infiltrate in EoE is patchy and that increasing numbers of biopsies increase
diagnostic sensitivity.61-64 Therefore, it is recommend for the endoscopist to obtain 2-4
biopsies from the distal esophagus and an additional 2-4 samples from the proximal
esophagus.1
Histologic features
Infiltration of the esophageal mucosa with eosinophils is the histologic hallmark of
EoE.65,66 Currently, finding at least 15 eosinophils per high-power microscopy field (eos/
hpf) is suggestive of EoE.1 However, as discussed in more detail below, the finding of
esophageal eosinophilia on biopsy is not specific for EoE. When biopsy samples are
examined, in addition to the eosinophil count which by convention represents the peak value
in the most highly inflamed area on the biopsy, other features are also present (Figure
2).1,65,66 Eosinophils are often found toward the apical aspect of the epithelium, and clusters
of eosinophils can form eosinophilic microabscesses. Because eosinophils are activated in
EoE, they degranulate and the granule proteins can be seen extracellularly. There is also
basal layer hypertrophy, where the cells in the basal layer expand and the rete pegs elongate.
Spongiosis, also termed dilated intracellular spaces, is frequently observed. Finally, if the
biopsy sample is deep enough to contain lamina propria, fibrosis of this area can be noted.
Diagnostic criteria
Consensus guidelines
Because of heterogeneity in disease definition and reporting of data pertaining of
EoE,28,67,68 an initial set of diagnostic guidelines were proposed in 2007 and represented a
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major step forward for the field.69 These guidelines have been recently updated after taking
into account advances in understanding and complexities related to diagnosis.1 In this most
recent document, EoE is defined conceptually as a “chronic immune/antigen-mediated
esophageal disease characterized clinically by symptoms related to esophageal dysfunction
and histologically by eosinophil-predominant inflammation”. Three specific criteria were
required to diagnose EoE:
• Symptoms related to esophageal dysfunction;
• A peak eosinophil count of ≥ 15 eos/hpf on esophageal biopsy, with few
exceptions;
• Eosinophilia limited to the esophagus with other causes of esophageal eosinophilia
excluded.
Taken together, the conceptual definition and the diagnostic criteria emphasize that EoE is a
clinicopathologic condition. Specifically, the entire clinical and histologic picture must to be
considered in order to make a diagnosis, and no single feature is diagnostic on its own.
Diagnostic dilemmas
Despite having a set of diagnostic guidelines, the ability to characterize patients clinically
and endoscopically, and well defined histologic findings with a marker, the eosinophil
count, that is reliable and reproducible if approached systematically,70 diagnosis of EoE can
still be challenging.
Just as symptoms of dysphagia and findings of esophageal rings on endoscopy are not
specific for EoE, there is a differential diagnosis for esophageal eosinophilia on biopsy.1,69
A number of conditions that have been reported to cause or be associated with esophageal
eosinophilia, such as achalasia, infections (fungal, viral, parasitic), connective tissue disease,
graft-versus host disease, Crohn’s disease, adrenal insufficiency, hypereosinophilic
syndrome, and eosinophilic gastroenteritis, have their own distinct clinical presentations and
can typically diagnosed with a focused history and physical exam and limited supplemental
evaluation. However, two conditions, gastroesophageal reflux-disease (GERD) and PPI-
responsive esophageal eosinophilia (PPI-REE) deserve special attention when attempting to
diagnose EoE.
There is substantial overlap between GERD and EoE, including symptoms of heartburn,
chest pain, and dysphagia, and biopsy findings of eosinophilia; even very high eosinophil
counts do not distinguish the two conditions.44,71 In the 2007 EoE diagnostic guidelines,
exclusion of GERD, either with a high-dose PPI trial or with pH monitoring, was required
prior to definitively diagnosing EoE.69 As more clinical experience was gained, it was clear
that there were some patients who had coexisting EoE and GERD and that the relation
between the two conditions was complicated.71
In addition, there was the observation that some patients who appeared to have EoE would
have a clinical and histologic response to PPI therapy. This was first reported in a case series
by Ngo and colleagues, and since then a number of studies have reported that one third or
more of patients with esophageal eosinophilia have a response to PPIs.72-77 This
phenomenon has been termed PPI-REE.1 It is not currently known whether this is a distinct
clinical entity, a sub-type of GERD, or phenotype of EoE, but it’s role must currently be
addressed in the diagnostic algorithm for EoE. Specifically, when esophageal eosinophilia is
found on biopsy in a clinical setting where there is suspicion for EoE, a high dose PPI trial
(20-40 mg twice daily of any of the available agents for 8 weeks) is necessary. If a patient
responds to this regimen, then additional clinical evaluation can be performed to determine
if GERD was the cause of the esophageal eosinophilia or if the patient has PPI-REE. If a
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patient has persistent symptoms of EoE and there are still at least 15 eos/hpf on esophageal
biopsy, than EoE can be diagnosed.
Because of these challenges and the somewhat rudimentary way in which EoE is diagnosed,
there is active research aimed at identifying better ways to diagnose EoE. Some methods
under investigation include clinical scoring systems,8,78,79 endoscopic imaging
techniques,56,80,81 functional luminal assessment of the esophagus,82 biomarker
measurements on esophageal biopsies,83-87 radio-labelling of esophageal biopsies,88 non-
invasive assessment of esophageal cytokines,89 non-invasive serum biomarkers,90-92 and
genetic testing.21,93 While these are promising, none of these techniques have been validated
or are ready to be used in clinical practice.
Treatment
There are now a number of evidence-based treatment options for EoE. Pharmacologic agents
are commonly used, but non-pharmacologic approaches such as dietary elimination therapy
and endoscopy dilation are also effective. Of note, there are currently no Food and Drug
Administration-approved medications for EoE, so all pharmacologic treatment options are
off-label. The overall goal of treating patients with EoE is to improve symptoms and
normalize the esophageal mucosa without adversely impacting quality of life, although
specific endpoints have been difficult to define in clinical trials.94 Because EoE is chronic,
for the majority of patients when medications or dietary therapy are stopped, symptoms will
recur.95-97 For this reason, in patients with severe, frequent, or recurrent symptoms, or in
patients who have had complications such as esophageal strictures, food impactions
requiring emergency evaluation for endoscopy and bolus clearance, or esophageal
perforations, long-term treatment may be required.
Pharmacologic treatment
Corticosteroids—Corticosteroid medications are an effective and commonly used
treatment for EoE (Figure 3). Initially, systemic steroids were administered with good
effect,95,98 but because of concerns about side effects, this class was not a viable option for
long-term used. Instead, a “topical” method of administration of steroids was developed.99
Patients were instructed to use asthma medication preparations, either in multi-dose inhaler
(MDI) or aqueous solution formulations, and instead of inhaling the medications they
swallowed them to coat the esophagus. With this technique, a number of studies showed that
agents like fluticasone, budesonide, mometasone, beclomethasone, and ciclesonide all
effectively decreased esophageal eosinophil counts and improved clinical symptoms.99-107
In addition, a randomized control trial (RCT) comparing topical fluticasone with prednisone
by Schaefer and colleagues showed that the two agents were equivalent for improving
symptoms and eosinophil counts.108
The two most commonly used topical steroids are fluticasone and budesonide. The first
placebo controlled RCT in EoE was conducted in children by Konikoff and colleagues using
fluticasone.109 They showed that 50% of the 21 subjects receiving fluticasone had complete
histologic remission (defined as ≤ 1 eos/hpf) compared with 9% of the 15 subjects receiving
placebo. Recently, a similar study was conducted in adults by Alexander and colleagues.110
Here, 62% of the 21 adults treated with fluticasone had a > 90% decrease in eosinophil
counts, compared with 0% of the 15 subjects in the placebo arm. When used clinically, the
typical dose of fluticasone is 880-1760 mcg/d, administered twice daily, with the final dose
determined by patient age or size.
Topical budesonide has also been studied. Here, the aqueous formulation of the medication
is typically mixed with a sugar substitute such as sucralose, and the resultant slurry (which
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has been termed oral viscous budesonide, or OVB) is swallowed.104,111 In the first RCT in
children, Dohil and colleagues reported that 87% of the 15 subjects who received OVB had
a histologic response (≤ 6 eos/hpf) where none of the 9 patients in the placebo group had this
response. The marked histologic response seen with budesonide was confirmed in a larger
placebo-controlled dose-finding trial of 80 children, but in this study, symptoms
significantly improved in both the active therapy and placebo arms, making the results
somewhat difficult to interpret and highlighting a trend that has been seen in some other
recent trials.112 There have also been two RCTs of budesonide in adults. Straumann and
colleagues compared a nebulized and then swallowed protocol for budesonide to placebo,
and found that budesonide was highly effective for improving symptoms and decreasing
eosinophil counts.113 The second study compared OVB to the nebulized/swallowed
budesonide administration protocol, and showed that OVB was more effective.114 When
used clinically, the typical dose of budesonide is 1-2 mg/d, mixed with 5g of sucralose and
administered twice daily, with the final dose determined by patient age or size.
Topical steroids are generally considered safe and well tolerated. Adrenal suppression has
not been reported with an initial course of treatment,110,112,114,115 but longer term safety
data are needed.1 The main adverse effect with topical steroids is local. The rate of candidal
esophagitis ranges from 0-32% in prospective studies, though many of these cases were
detected incidentally on follow-up endoscopy.108-110,112-115 There is also a case report of
herpes esophagitis complicating topical steroid use.116
Biologic agents—There has been burgeoning interest in non-steroid treatment modalities
for eosinophilic esophagitis, and biologic agents targeting key factors in the pathogenesis of
EoE are intriguing options. To date, however, these are either still in the experimental phase
or have not been shown to be effective.
Mepolizumab and reslizumab are monoclonal anti-IL-5 antibodies. A small series showed
that mepolizumab had some efficacy for EoE, so these agents were subsequently studied in
three RCTs, one in adults and two in children.117-119 While there was a mild to moderate
improvement in eosinophils counts, the medications did not tend to improve symptoms in
the active treatment arms compared to placebo, and primary endpoints of resolution of
eosinophilia and symptoms were not met. These agents are not available clinically at this
time.
Infliximab, an anti-tumor necrosis factor (TNF) antibody frequently used in inflammatory
bowel disease, was examined in a small case series of steroid-refractory EoE patients, but
did not improve symptoms or histology.120
Omalizumab, a monoclonal antibody against IgE and used for allergic asthma, was studied
in a placebo-controlled RCT by Fang and colleagues in 30 adults with EoE.121 There was no
difference in any of the outcomes between the groups, and this agent is not recommended
for use in EoE.
Other agents—Given the strong association between EoE and allergic diseases,
leukotriene antagonists have been studied, but the data are conflicting. In an initial report in
adults by Atwood and colleagues, high doses of montelukast (20-40 mg/d) were effective,
though associated with nausea and vomiting.122 Two additional studies, one in adults and
one in children, were less encouraging,123,124 and this agent is not routinely used in EoE.
Mast cell stabilizers such as cromolyn have also been examined, but were not effective.29
There are currently no data in EoE for ketotifen, an anti-histamine with anti-mast cells
properties.
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Immunomodulators such as azathioprine and 6MP have been studied in a single series of
three patients with steroid-dependent EoE.125 While the medication was effective for
improving eosinophilic counts and maintaining symptom control, given the potential toxicity
and paucity of data, this medication is not recommended for routine use in EoE.
A number of investigations into novel agents to treat EoE are ongoing. For example, anti-
IL-13 and anti-eotaxin-3 antibodies are under development,1 and pilot data were recently
presented on a Th2 cell prostaglandin D2 receptor antagonist, which represents a potentially
new medication class for EoE.126 With the increasing understanding of pathways involved
in the pathogenesis of EoE, it is likely that a wide variety of therapeutic modalities will be
studied over the coming years.
Non-pharmacologic treatment
There are two major strategies for non-pharmacologic treatment of EoE. The first is dietary
elimination, where specific foods or groups of foods are removed from the diet in order to
identify potential food allergens that trigger EoE. Similar to pharmacologic therapy, dietary
restriction reduces esophageal eosinophilia. The second is endoscopic dilation, where
strictures, rings, or a narrow-caliber esophagus are stretched in order to relieve symptoms of
dysphagia. This technique does not impact the underlying inflammation in the esophagus.
Dietary elimination—There are three approaches to dietary elimination for treatment of
EoE. First is a completely allergen-free elemental formula, composed of only amino acids,
medium chain triglycerides, and simple carbohydrates. This treatment was initially used in
one of the early reports of EoE where ten children responded within weeks of starting the
formula.5 In a study of 51 children, Markowitz and colleagues found that 96% of subjects
had near-complete resolution of esophageal eosinophilia and symptoms within 1-2
weeks,127 and other studies have reported similar results.29,128 Until recently, all of the data
on elemental diets were in children, but a study by Peterson and colleagues confirms the
short-term utility of this approach in adults as well, if they can tolerate the formulation.129
Though elemental diets are very effective for EoE treatment, they are unpalatable,
expensive, sometimes require gastrostomy tubes for administration, and may not be feasible
for many patients with EoE.
The second approach, the so-called six food elimination diet (SFED), addresses the
difficulty with compliance found with the elemental diet. In the SFED, the six most highly
allergenic food groups, dairy, egg, wheat, soy, nuts, and seafood, are removed from the diet.
This approach compares quite favorably with the elemental diet in children, with three-
quarters of subjects having resolution of esophageal eosinophilia and almost all having
improvement in symptoms.128,130,131 Gonsalves and colleagues have now shown that the
SFED is equally effective in adult patients as well.132
Third is a targeted elimination diet where foods are removed based on reactivity on allergy
testing. This is less restrictive than either elemental or SFED diets, but the efficacy is also
somewhat less, likely due to the fact that allergy testing itself is not completely reliable for
detecting food triggers.1,128,133 A number of studies have explored this approach, and the
overall response rate ranges between 50-75% in children and lower in adults, depending on
the center and the methods of allergy testing used.29,128,134-138
When selecting dietary modification as the treatment modality for a patient with EoE, it is
important to have a multidisciplinary approach with collaboration between
gastroenterologists, allergists, and nutritionists. This ensures not only that patients are
having their nutrition requirements met, but that they have enough information about food
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choices and potential sources of contamination to maximize the likelihood of success of the
elimination diet.
Endoscopic dilation—Endoscopic dilation is an effective way to treat dysphagia due to
strictures or narrow caliber esophagus in patients with EoE (Figure 4). When the technique
was first reported, however, there were high rates of complications such as esophageal
perforation, mucosal rents, and hospitalization for post-procedural chest pain, and safety was
a significant concern.52,53,139-142 As more experience with dilation in EoE patients has
accumulated, however, the technique appears safer than originally believed and a cautious
approach has been endorsed.1 In a number of recently published studies and two systematic
reviews,143-151 the overall perforation rate is 0.3%, which is similar to the cited rate for
upper endoscopy with dilation in patients who do not have EoE.152
Dilation is also consistently reported to improve symptoms of dysphagia, even though the
underlying eosinophilic inflammation is not affected.147,148,150,151 In one study by
Schoepfer and colleagues, after one dilation session and in the absence of other medical or
dietary treatments, the symptom response after dilation persisted for 1 year in 46% and for 2
years in 41%.147 This same study also observed that if patients are asked prospectively,
approximately three-quarter will report post-dilation chest discomfort.
There are few data on the timing of dilation. Unless there is a critical stricture noted on the
first endoscopy, dilation of a narrow-caliber esophagus is typically postponed until the
follow-up endoscopy assessing the effect of medical or dietary therapy.1,69 There are also
few data on the specific dilation technique, and both balloon and bougie dilation have been
reported to be effective.148,153,154 Therefore regardless of the equipment choice, dilation
should be approached with caution, care should be taken in choosing the initial dilator size,
dilator size should not be increased after a mucosal rent is created, and patients should be
informed about the risk, benefits, and likelihood of discomfort after the procedure.
Treatment non-response
While the majority of patients respond to medical or dietary therapy, there are a proportion
who remain refractory to therapy. In these cases, a systematic assessment should be made to
identify the reason for non-response, specifically determining whether ongoing esophageal
eosinophilia is the cause of symptoms or if there are other contributing factors. Potential
reasons for non-response include:
• Non-adherence to the prescribed treatment
• Inadequate dosing of a topical steroid
• Candidal esophagitis complicating steroid therapy. In these cases, the eosinophilic
inflammation has typically improved, but the infection causes dysphagia and
odynophagia.
• Persistent esophageal stricture or narrowing. Here, the eosinophilic inflammation
has also resolved, but fibrotic changes in the esophagus remain and require dilation
therapy for symptom improvement. Many times, subtle narrowing can be difficult
to appreciate on endoscopic examination.
• Superimposed motility disorders. While there is not a single characteristic pattern
of esophageal dysmotility in EoE, esophageal longitudinal muscle dysfunction has
been reported in a subset of patients with EoE,155-157 and the esophagus is also less
compliant in EoE patients.82
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• Persistent esophageal eosinophilia that is truly refractory to therapy. This could be
due to failure to respond to adequate doses of steroid medications, or due to
persistent (or inadvertent) allergen exposure. In this situation, if a patient has failed
topical steroid therapy, they should be tried on dietary elimination. Conversely, if
they have failed dietary therapy, they should be placed on topical steroids.
Summary
Eosinophilic esophagitis is a chronic allergen-mediated disorder defined by symptoms of
esophageal dysfunction and epithelial eosinophilia on biopsy. It has rapidly emerged as an
important cause of upper GI morbidity in patients of all ages and is encountered in a
substantial proportion of patients undergoing diagnostic upper endoscopy.
Diagnosis of EoE is based on consensus guidelines, but can be challenging because none of
the symptoms, endoscopic findings, or histologic features are specific for EoE on their own.
From a practical standpoint, EoE is suspected when a patient presents with symptoms of
dysphagia, food impaction, or in children with feeding intolerance, abdominal pain, or
vomiting. There are often concomitant atopic disorders present. On endoscopic evaluation,
typical findings include rings, furrows, white plaques or exudates, decreased vascularity or
congestion, esophageal narrowing or strictures, and mucosal fragility. When biopsies reveal
at least 15 eos/hpf, EoE is a diagnostic consideration. However, other causes of eosinophilic
must be considered and in particular, PPI-REE must be excluded with a PPI trial for 8 weeks
and a repeat endoscopy. If symptoms persist and biopsies continue to show a peak of at least
15 eos/hpf after the PPI trial, then EoE is diagnosed.
For treatment, either swallowed topical corticosteroids or dietary elimination therapy are
reasonable first line options. The choice will depend both on patient preference and local
expertise. In cases where there are severe esophageal strictures, dilation is also performed.
After an initial trial of treatment for 8 weeks, a follow-up endoscopy is useful to assess the
mucosal response to the anti-eosinophil treatment and to determine if further endoscopic
dilation is required. For patients who do not respond to either dietary or medical treatment,
there are limited options but a number of new agents are under investigation and will likely
change the treatment algorithm in the future.
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• Over the past ten years, EoE has become a major cause of GI symptoms,
including dysphagia and food impaction in adolescents and adults, and feeding
intolerance, failure-to-thrive, regurgitation, heartburn, and vomiting in children.
• EoE is a clinicopathologic condition, so the entire clinical and histologic picture
must to be considered in order to make a diagnosis; no single feature is
diagnostic on its own.
• EoE is now diagnosed based on consensus guidelines requiring symptoms of
esophageal dysfunction, at least 15 eosinophils per high-power microscopy field
on esophageal biopsy, and eosinophilia limited to the esophagus with other
causes of esophageal eosinophilia (including proton pump inhibitor responsive
esophageal eosinophilia) excluded.
• Effective first line treatment strategies include topical steroids, such as
swallowed fluticasone or budesonide, or dietary therapy with either an elemental
formula, a six-food elimination diet, or a targeted elimination diet.
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The range of endoscopic findings in EoE. (A) A patient with an acute food bolus impaction.
(B) After the bolus is cleared, fixed esophageal rings are noted. (C) A patient with less
prominent esophageal rings. (D) Felinization of the esophageal with rings that are transiently
present. Congestion and loss of vascular marking area also noted. (E) A narrow caliber
esophagus which prevented passage of an adult upper endoscope. Rings, congestion, and
decreased vasculature are also present. (F) Linear furrows in the distal esophagus, associated
subtle rings and decreased vasculature. (G) Prominent white plaques and exudates, as well
as subtle rings and furrows. In this patient, brushings were negative for candida and biopsies
showed multiple eosinophilic microabscesses. (H) Crêpe-paper mucosa where this tear was
noted after uneventful passage of the endoscope. The mucosa is also congested with
decreased vascularity. (I) A patient with multiple findings of rings, furrows, decreased
vascularity, narrow caliber esophagus, and crêpe-paper mucosa.
Dellon Page 23














Esophageal biopsy specimen in EoE. This shows a brisk eosinophilic infiltration in the
esophageal epithelium, as well as spongiosis (+), eosinophil degranulation (arrowhead),
basal zone hyperplasia (bracket), and an eosinophilic microabscess (*).
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(A) Endoscopic appearance of the esophagus prior to topical steroid therapy with rings,
furrows, and degreased vascularity noted. (B) Appearance has completely normalized after
topical steroid therapy. A similar improvement is noted on this patients biopsies before (C)
and after (D) treatment.
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Dilation for treatment of EoE. (A) Endoscopic appearance of a esophageal narrowing with a
tight series of rings, as well as mucosal pallor, congestion, and decreased vasculature. (B)
Through-the-scope balloon deployed and inflated to 10 mm. (C) Desired post-dilation effect
with mucosal disruption.
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